The first one may be dependent on the mutation status of genes such as Pten or p53, and the latter has been recently studied as determinant of drug penetration (a summary of QCT effects combined with a status of mutations in crucial cancer progression-related genes in several GBM cell lines is presented in Table 1). The gene discussed is TP53; the disease is glioblastoma.